Albert Labs International (FRA:VB50) DeferredTaxAndRevenue: €0.00 Mil (As of Sep. 2023)


What is Albert Labs International DeferredTaxAndRevenue?

Albert Labs International FRA:VB50 DeferredTaxAndRevenue is €0.00 Mil as of Sep. 2023.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Albert Labs International's current deferred tax and revenue for the quarter that ended in Sep. 2023 was €0.00 Mil.

Albert Labs International DeferredTaxAndRevenue Related Terms

Albert Labs International DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Albert Labs International's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Albert Labs International DeferredTaxAndRevenue Chart

Albert Labs International Annual Data
Trend Dec21 Dec22
DeferredTaxAndRevenue
0.00 0.00

Albert Labs International Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of €0.00 Mil mean?
Albert Labs International (FRA:VB50) has a DeferredTaxAndRevenue of €0.00 Mil as of Sep. 2023. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Albert Labs International.
Is Albert Labs International's DeferredTaxAndRevenue too high?
Albert Labs International's current DeferredTaxAndRevenue is €0.00 Mil.
How does Albert Labs International's DeferredTaxAndRevenue compare to VRTX and REGN?
Albert Labs International's DeferredTaxAndRevenue of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Albert Labs International. Albert Labs International's current DeferredTaxAndRevenue is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Albert Labs International stock overvalued right now?
Albert Labs International (FRA:VB50) has a current DeferredTaxAndRevenue of €0.00 Mil. The current DeferredTaxAndRevenue is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Albert Labs International (FRA:VB50), the current DeferredTaxAndRevenue is €0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Albert Labs International Business Description

Address 201-6996 Merritt Avenue, Burnaby, BC, CAN, V5J 4R6
Albert Labs International Corp is a laboratory-based, clinical research, and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of a clinical pathway.